Open Access | Interview
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Cytomegalovirus and age-related disease conditions——an interview with Prof. Patricia Price
* Corresponding author: Ying Li
Mailing address: Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province,
China.
Email: nancy_942@163.com
Received: 06 June 2024 / Accepted: 11 June 2024 / Published: 27 June 2024
DOI: 10.31491/APT.2024.06.146
Abstract
The article is an interview with Prof. Patricia Price of the Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia conducted by Ying Li et al. from the Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China, on behalf of Aging Pathobiology and Therapeutics.
Patricia Price, MD
Prof. Patricia Price is a professor of immunology at University of Western Australia and an immunologist based
at Curtin University in Perth. She has been engaged in
immune related virus for over 40 years. The research has
addressed the immunopathogenesis of viral diseases – notably Cytomegalovirus (CMV) and HIV. Since beginning her
research in Asia in 2008, Professor Price has designed and
run studies addressing co-infection with HIV and other
viruses in a developing world setting. In addition, another
research direction is to seek mechanisms that may alter
the immune footprint of HCMV in individuals, providing
new directions and ideas for further research and improvement of viral host interaction mechanisms. Patricia
Price is also the author or editor of more than 300 articles in medical journals. (https://staffportal.curtin.edu.au/staff/profile/view/patricia-price-88ee06d7/).
Ying Li et al.: Hello, Prof. Price, nice to meet you. We are
attending physicians from the Department of Neurology,
First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. Our team is now under the
research field of immunosenescence on neurology, which
is related to your research field. First of all, can you give a
general introduction to your research direction?
Patricia Price: My research has addressed the immunopathogenesis of viral diseases – notably cytomegalovirus
and HIV. This response will focus on CMV as 60-80% of
all people in the world are CMV seropositive. The virus
replicates the salivary gland so nobody can remain unexposed. CMV encodes homologues of several human genes
implicated in immunoregulation and consequently affects
the hosts immune system in a dose-dependent manner. In
addition, successive CMV reactivations throughout life
stimulate T-cell responses and hence drive immunosenescence. Hence CMV should be considered in all evaluation
of the immune system in old age. These changes occur at a
younger age in people living with HIV. Metrics of the burden of CMV associate with many diseases of aging – most
notably cardiovascular disease.
Ying Li et al.: That sounds very interesting. Many patients
in our department also have cardiovascular diseases. However, we never pay attention to their CMV burden. We
have read many of your papers and know that you have
done wonderful work on the interactions between CMV
and cells of the immune system [1]. What made you switch
to kidney transplant patients and evaluate the role of the CMV footprint in cardiovascular health according to your
publication [2]?
Patricia Price: Kidney transplant patients have a high
burden of CMV so changes are likely to be most apparent
in these people. The focus on CVD was partly driven by
available funding, but is a logical progression. Issues with
a clinical impact should be chosen when they are amenable
to scientific study.
Ying Li et al.: Yes, we agree with that. Your work has pioneered the study of the relationship between cardiovascular
disease and CMV, which is a huge field. When you were
studying the pathological consequences of the CMV footprint, did you ever think that your work would become a
landmark in the development of this field? Do you think
there is still work to be done in this area? In future research, will your laboratory continue to explain individual
differences in cardiovascular disease by CMV response according to your publication [3]?
Patricia Price: One always hopes to do work described as
“landmark” but one should not give up hope as long as
publications are passing peer review in acceptable journals. The important thing is to think hard about your own
data and about what you are reading, and then write clearly so that every paper tells a story. I do believe that CMV
influences CVD, but issues around assessment of the burden of CMV in an individual are too often overlooked.
Ying Li et al.: Yes. As attending physicians, it is a little
difficult for us to publish many papers due to the little research time and hard clinical work. We will try to focus
our work on a specific area as you have done. I think it
would be helpful to use our limited research time. As we
know, you started studying the pathogenesis of neurological disorders in HIV patients 20 years ago [4]. I think this
is a huge and very important topic. What drives you to do
this innovative and transformative work?
Marco G. Alves: HIV-associated neuropathy was presented
to me as a topic that had received too little attention. We
were eventually able to determine the risk factors in South
Africans and South East Asia. This included genetic studies which shed light on the pathogenesis – made possible
by some awesome collaborations. However the condition is
now rare (as HIV is treated early), so the work has largely
stopped. It will be interesting to see whether the pathogenic mechanisms that we identified influence other forms
of neuropathy.
Ying Li et al.: As you know, in China, HIV patients are
well managed and treated. In our department, we can hardly meet HIV patients with neuropathy. We agree that the
mechanisms of HIV-associated neuropathy are interesting,
although difficult. Meanwhile, we have noticed that you
have had a remarkable career. How do you evaluate your
journey so far? What are your future goals and other passions?
Patricia Price: My main goal now is to help the next generation of young scientists. It is their turn to take the work
forward.
Ying Li et al.: Sounds great. We really need help from famous scientists like you. We also hope to have some collaborations in the future. In the area of aging research, how
does the immune system change with age and what are the
implications of these changes for aging?
Patricia Price: There is an abundant literature addressing this question. The usual mantra is that existing B-cell
responses are maintained, whilst T-cell responses decline
faster. This mirrors the effects of CMV on the immune
system. Measures of the burden of CMV will be informative.
Ying Li et al.: Our research is related to immunosenescence. In your opinion, what is the significance and research value of immunosenescence in relation to clinical
diseases?
Patricia Price: I am not clear what you are asking here, but
it is pertinent to note that T-cells change their functional
profiles as they differentiate. For example; TEMRA (marked
by the phenotype CD28-
, CD45RA+
) produce interferonefficiently but proliferate poorly. Hence the term “immunosenescence” has gone out of favor.
Ying Li et al.: Since age-related diseases such as Alzheimer’s and Parkinson’s are associated with changes in the
immune system, the COVID-19 pandemic poses a huge
challenge to the immune system of the elderly. Can you
talk about the impact of this pandemic on the progression
of these age-related diseases?
Patricia Price: I am not an expert on COVID-19, but believe that it has potential to alter the immune system itself
and to promote the replication of other viruses such as
CMV. This highlights the importance of COVID-19 vaccinations.
Ying Li et al.: Since we know that changes in the immune
system are associated with Alzheimer’s disease, can you
talk about whether damage to the blood-brain barrier plays
a role in the process of Alzheimer’s disease?
Patricia Price: The continuum between vascular dementia
and Alzheimer’s disease is a topic of extensive research
in the last decade. Inflammation is likely to play a role,
so there is a potential for enhancement by many viral diseases. Our research suggests a role for CMV, but the effect
is complicated as CMV-reactive antibodies appear to be
protective. CMV certainly crosses the blood brain barrier.
Ying Li et al.: Thanks for your time!
References
1. Affandi JS, Aghafar ZK, Rodriguez B, Lederman MM, Burrows S, Senitzer D, et al. Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus-infected patients? Hum Immunol, 2012, 73(2): 168-174. [Crossref]
2. Karim B, Wijaya IP, Rahmaniyah R, Ariyanto I, Waters S, Estiasari R, et al. Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART. AIDS Res Ther, 2017, 14(1): 52. [Crossref]
3. Waters S, Allcock RJN, Lee S, Downing J, Ariyanto I, Leary S, et al. Do variations in the HLA-E ligand encoded by UL40 distinguish individuals susceptible to HCMV disease? Hum Immunol, 2023, 84(2): 75-79. [Crossref]
4. Almeida CA, Price P, & French MA. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 2002, 18(18): 1351-1355. [Crossref]